Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH3127 in mild-moderate essential hypertension
NCT03756103Phase 2Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jan 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sitokiren in essential hypertension, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Jan 2019; status: completed.
02
Drugs
sitokiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT03756103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03756103.